Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues - PubMed (original) (raw)
Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin-embedded tissues
S Kumar et al. Mod Pathol. 2000 Sep.
Abstract
Myogenin belongs to a group of myogenic regulatory proteins whose expression determines commitment and differentiation of primitive mesenchymal cells into skeletal muscle. The expression of myogenin has been demonstrated to be extremely specific for rhabdomyoblastic differentiation, which makes it a useful marker in the differential diagnosis of rhabdomyosarcomas (RMS) from other malignant small round cell tumors of childhood. Commercially available antibodies capable of detecting myogenin in routinely processed formalin-fixed paraffin-embedded (FFPE) tissue are now available. In this study, we evaluated myogenin expression using the monoclonal myf-4 antibody (Novocastra Labs) on FFPE in a large number of pediatric tumors in order to define the clinical utility of this marker. A total of 119 tumors were studied. These included 48 alveolar RMS (ARMS), 20 embryonal RMS (ERMS), one spindle cell RMS, 16 Ewing's sarcomas (ES), six nephroblastomas, two ectomesenchymomas, seven precursor hematopoietic neoplasms, five olfactory neuroblastomas, three neuroblastomas, six desmoplastic small round cell tumors, and five rhabdoid tumors. Distinct nuclear staining for myogenin was noted in all 69 RMS. Notably, the number of positive tumor cells differed between the ARMS and ERMS. In ARMS, the majority of tumor cells (75 to 100%) were positive, in contrast to ERMS, in which the positivity ranged from rare + to 25% in all but three tumors. Additionally, myogenin positivity was seen in two of two ectomesenchymomas and in two nephroblastomas with myogenous differentiation. All other tumors were clearly negative. Our results indicate that staining for myogenin is an extremely reliable and specific marker for rhabdomyoblastic differentiation. It gives consistent and easily interpretable results in routinely fixed tissues.
Similar articles
- Immunohistochemical analysis of a muscle ankyrin-repeat protein, Arpp, in paraffin-embedded tumors: evaluation of Arpp as a tumor marker for rhabdomyosarcoma.
Ishiguro N, Motoi T, Osaki M, Araki N, Minamizaki T, Moriyama M, Ito H, Yoshida H. Ishiguro N, et al. Hum Pathol. 2005 Jun;36(6):620-5. doi: 10.1016/j.humpath.2005.04.014. Hum Pathol. 2005. PMID: 16021567 - Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma.
Paner GP, McKenney JK, Epstein JI, Amin MB. Paner GP, et al. Am J Surg Pathol. 2008 Jul;32(7):1022-8. doi: 10.1097/PAS.0b013e3181650e4a. Am J Surg Pathol. 2008. PMID: 18469707 - [Rhabdomyosarcoma and extraosseous Ewing's sarcoma].
Harms D, Leuschner I, Krams M, Pilgrim TB, Treuner J. Harms D, et al. Verh Dtsch Ges Pathol. 1998;82:83-98. Verh Dtsch Ges Pathol. 1998. PMID: 10095421 Review. German. - Rhabdomyosarcoma subtyping by immunohistochemical assessment of myogenin: tissue array study and review of the literature.
Morgenstern DA, Rees H, Sebire NJ, Shipley J, Anderson J. Morgenstern DA, et al. Pathol Oncol Res. 2008 Sep;14(3):233-8. doi: 10.1007/s12253-008-9012-5. Epub 2008 May 21. Pathol Oncol Res. 2008. PMID: 18493875 Review.
Cited by
- A Multi-Dimensional Approach to Map Disease Relationships Challenges Classical Disease Views.
Möbus L, Serra A, Fratello M, Pavel A, Federico A, Greco D. Möbus L, et al. Adv Sci (Weinh). 2024 Aug;11(30):e2401754. doi: 10.1002/advs.202401754. Epub 2024 Jun 5. Adv Sci (Weinh). 2024. PMID: 38840452 Free PMC article. - Orbital Rhabdomyosarcoma Masquerading as a Dermoid Cyst: A Case Report and Review of the Literature.
Karakosta C, Liaskou M, Kattamis A, Rigatou E, Paraskevopoulos K. Karakosta C, et al. Cureus. 2023 Dec 11;15(12):e50332. doi: 10.7759/cureus.50332. eCollection 2023 Dec. Cureus. 2023. PMID: 38205487 Free PMC article. - A dysfunctional miR-1-TRPS1-MYOG axis drives ERMS by suppressing terminal myogenic differentiation.
Hüttner SS, Henze H, Elster D, Koch P, Anderer U, von Eyss B, von Maltzahn J. Hüttner SS, et al. Mol Ther. 2023 Sep 6;31(9):2612-2632. doi: 10.1016/j.ymthe.2023.07.003. Epub 2023 Jul 14. Mol Ther. 2023. PMID: 37452493 Free PMC article. - Vitamin D inhibits osteosarcoma by reprogramming nonsense-mediated RNA decay and SNAI2-mediated epithelial-to-mesenchymal transition.
Capobianco E, McGaughey V, Seraphin G, Heckel J, Rieger S, Lisse TS. Capobianco E, et al. Front Oncol. 2023 May 9;13:1188641. doi: 10.3389/fonc.2023.1188641. eCollection 2023. Front Oncol. 2023. PMID: 37228489 Free PMC article. - Quantitative proteomic studies addressing unmet clinical needs in sarcoma.
Connolly EA, Grimison PS, Horvath LG, Robinson PJ, Reddel RR. Connolly EA, et al. Front Oncol. 2023 May 1;13:1126736. doi: 10.3389/fonc.2023.1126736. eCollection 2023. Front Oncol. 2023. PMID: 37197427 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources